| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 Readout example | Phase 3 | — | Subscribe to access the data. | Nanomedicine | Ophthalmologic System | ||
Phase 3 Readout example | Phase 3 | — | Subscribe to access the data. | Nanomedicine | Ophthalmologic System | ||
Phase 3 Readout example | Phase 3 | — | Subscribe to access the data. | Nanomedicine | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Annexon, Inc.$5.8
-0.15 (-2.53%)
C 53Pipeline Score Fair Value Pharma · Clinical
Market Cap
861.81 M
EPS
-1.22
P/E Ratio
-4.33 $
Value Trade
15.65 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
35.79 M
Operating CF
-46.80 M
Total Assets
262.89 M
Total Liabilities
58.35 M
Equity
204.53 M
D/E Ratio
12,345
1.14 %
Week
-15.85 %
1 Month
5.15 %
3 Month
23.78 %
6 Month
-75.93 %
5 Year
-69.48 %
All Time
Cash Data
Cash Position
225.03 M
Monthly Burn
15.60 M
Runway
12.5 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
2.74 M
52 Week Range
1.85 - 7.18
% held by Insiders
13.03 %
% held by Institutions
89.72 %
Enterprise Value
662.22 M
Total Shares
119.70 M
Short %
18.52 %
Float Shares
86.06 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Annexon, Inc.
318Total events
5Upcoming
73Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 5
Event history 313
Jun 9, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
Jun 3, 2026
May 13, 2026
◆Oral PresentationPresentation
Annexon to present at Bank of America Securities Health Care Conference 2026
Apr 15, 2026
◆Oral PresentationPresentation
Annexon to present at 25th Annual Needham Virtual Healthcare Conference
Q2 2026
◆Topline ReadoutVonaprumentClinical Data
Pivotal Phase 3 topline data for vonaprument in GA
Dry AMD with Geographic Atrophy (GA)source ↗
Mar 30, 2026
●EU MAA SubmissionTanruprubartEx-US Regulatory
MAA filed with EMA for tanruprubart in GBS
Guillain-Barré syndrome (GBS)source ↗
Mar 18, 2026
◆Oral PresentationVonaprumentPresentation
KOL event to discuss vonaprument for GA
geographic atrophysource ↗
Mar 3, 2026
◆Oral PresentationPresentation
Annexon to present at TD Cowen 46th Annual Health Care Conference
Drug Pipeline Intelligence
C53
Pipeline Score $910M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored1.1x
rNPV / MCap Top 81%
Micro Cap (rank 174 of 911)
Percentile RankAnnexon, Inc. carries a moderate pipeline score (53/100), with $2.3B risk-adjusted pipeline value, led by ANX005 in Guillain-Barre Syndrome (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANX005 Small molecule | Guillain-Barre Syndrome | Phase 3 | NCT04701164 | 60% | $1.0B | COMPLETED | 242 | - | - | Apr 20, 2024 | - | May 29, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ANX005 Fast TrackOrphan | Guillain-Barr Syndrome | Phase 3 | 2025-03-03 | early and durable functional improvements with a differentiated safety profile Read More | Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Tar Read More | |
ANX005 Fast TrackOrphan | Guillain-Barr Syndrome | Phase 3 | 2025-03-03 | early and durable functional improvements with a differentiated safety profile Read More | Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Tar Read More | |
ANX005 Fast TrackOrphan | Guillain-Barr Syndrome | Phase 3 | 2025-03-03 | early and durable functional improvements with a differentiated safety profile Read More | Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Tar Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANNX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ANNX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ANNXAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. has granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan. This grant, amounting to options for 705,000 shares of common stock at an exercise price of $4.64, supports the company's commitment to enhance its workforce. The options are set to vest over four years, promoting employee retention. This move coincides with Annexon’s mission to deliver targeted immunotherapies to those suffering from neuroinflammatory diseases worldwide.
Read more →ANNXAnnexon to Participate in Upcoming June Investor Conferences
Annexon, Inc. announced its participation in two upcoming investor conferences in June 2026. Douglas Love, the CEO, will engage in fireside chats at the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. The presentations will be accessible via live webcasts and archived for later viewing.
Read more →ANNXAnnexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. reported its first quarter 2026 financial results and highlighted key milestones in its portfolio. The company anticipates pivotal Phase 3 data for vonaprument for Geographic Atrophy in Q4 2026 and is awaiting EU approval for tanruprubart as a therapy for Guillain-Barré Syndrome. Additionally, proof-of-concept data for ANX1502 is expected in 2026, supported by a strong financial position.
Read more →ANNXAnnexon to Present at the Bank of America Securities Health Care Conference 2026
Annexon, Inc. will present at the Bank of America Securities Health Care Conference on May 13, 2026. Douglas Love, the CEO, will discuss the company's advancements in targeted immunotherapies for neuroinflammatory diseases. A live webcast will be available, and a replay will be archived for 30 days. This presentation aims to showcase Annexon's innovative approach to treating serious conditions affecting millions.
Read more →ANNXAnnexon to Present at the 25th Annual Needham Virtual Healthcare Conference
Annexon, Inc. will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. Douglas Love, the CEO, will discuss the company's advancements in targeted immunotherapies for neuroinflammatory diseases. The event will be accessible via a live webcast, with a replay available for 30 days post-presentation.
Read more →ANNXAnnexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Po
Annexon announced its fourth quarter and year-end 2025 financial results, detailing significant progress in its drug pipeline, including the expected ARCHER II Phase 3 data for vonaprument in Q4 2026. The company filed for Marketing Authorization for tanruprubart in Europe, aiming to be a leading therapy for Guillain-Barr syndrome. Despite financial losses amounting to $48.3 million in Q4 2025, Annexon reported a strong cash position of approximately $238 million, which will facilitate its operations into mid-2027 as it advances its pivotal clinical programs.
Read more →ANNXAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. has announced the grant of an inducement equity award to a new non-executive employee under the Nasdaq Listing Rule 5635(c)(4). The award consists of an option to purchase 20,000 shares at an exercise price of $5.66, which was the closing price of the stock on the grant date. The option has a ten-year term and will vest over four years. This move aligns with Annexon's dedication to advancing therapies for neuroinflammatory diseases.
Read more →ANNXAnnexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
Annexon Biosciences will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. CEO Douglas Love will discuss the company's innovative platform of targeted immunotherapies aimed at neuroinflammatory diseases. The event will be accessible via a live webcast and archived for 30 days. Annexon focuses on addressing serious conditions affecting millions globally.
Read more →ANNXAnnexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
Annexon, Inc. is set to host a key opinion leader (KOL) event on March 18, 2026, to discuss vonaprument, a novel therapy for geographic atrophy associated with dry AMD. The event will feature expert presentations and a Q&A session. Vonaprument is currently undergoing a Phase 3 trial, with topline data expected in late 2026.
Read more →ANNXAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
Annexon, Inc. has announced the granting of inducement equity awards to two new non-executive employees under its 2022 Employment Inducement Award Plan. The options, totaling 155,000 shares, have a ten-year term and an exercise price of $6.16. These awards are part of Annexon's strategy to attract talent while advancing its targeted immunotherapies for neuroinflammatory diseases.
Read more →ANNX▲ +7.9%on this newsshared move
STOPPING NEUROINFLAMMATION AT ITS SOURCE TH 44 ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 2026 Nasdaq: ANNX 2025 Annexon, Inc. All rights reserved Forward-Looking Statements This presentation contains forwardlo oki
Annexon, Inc. presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its late-stage pipeline targeting neuroinflammatory diseases. The company has two promising product candidates, Vonaprument and Tanruprubart, which are positioned to potentially transform treatment paradigms. Vonaprument may be the first drug approved for dry age-related macular degeneration (AMD) with geographic atrophy, addressing a crucial market need. Despite these opportunities, Annexon faces various risks, including the uncertainties associated with clinical trials and regulatory approvals.
Read more →ANNX▲ +5.9%on this news· ran to +18% by day 1shared move
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 Tanruprubart MAA Filed with Potential to Be the First Targe
Annexon, Inc. has outlined its strategic priorities for 2026, focusing on the advancement of targeted immunotherapies for neuroinflammatory diseases. The company has filed a Marketing Authorization Application for tanruprubart, aiming to become the first fast-acting therapy for Guillain-Barr Syndrome, while also preparing for pivotal Phase 3 trials for vonaprument, expected to preserve vision in patients with dry age-related macular degeneration. These initiatives are bolstered by a strong financial position allowing operations to continue into late 2027. Annexon expresses confidence in achieving significant milestones that could improve treatment outcomes for millions of patients.
Read more →ANNX▲ +8.4%on this newsshared move
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Annexon Biosciences announced that CEO Douglas Love will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is developing targeted immunotherapies aimed at neuroinflammatory diseases that affect nearly 10 million people globally. The presentation will be available via a live webcast and will be archived for 30 days. Annexon’s therapies focus on mitigating classical complement-driven neuroinflammation to restore function and improve patient outcomes.
Read more →ANNXAnnexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
Annexon, Inc. has successfully closed its public offering of 29,423,075 shares, raising approximately $86.25 million before expenses. This offering included the full exercise of underwriters’ option for additional shares. The offering is part of a shelf registration that was filed and declared effective by the SEC earlier this year, allowing Annexon to make strategic capital moves for its ongoing development of therapies targeting neuroinflammation.
Read more →ANNX▼ -5.6%on this newsshared move
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Annexon, Inc. has announced the pricing of a public offering of 25,096,153 shares of common stock at $2.60 per share, along with pre-funded warrants for an additional 3,750,000 shares. The total expected gross proceeds from the offering are $75 million, set to close on November 14, 2025. The offering is managed by Goldman Sachs, TD Cowen, and Wells Fargo Securities.
Read more →ANNXAnnexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Annexon, Inc. has announced a proposed public offering of $75 million worth of common stock and pre-funded warrants. The offering is subject to market conditions and involves a potential additional $11.25 million if underwriters exercise their option. The securities will be offered under an effective registration statement with the SEC. This move is intended to bolster Annexon's operations and developments in treating neuroinflammatory diseases, yet the uncertainty of market conditions poses a risk.
Read more →ANNXAnnexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. reported its third quarter 2025 financial results, highlighting progress in its late-stage neuroinflammation platform. The company is preparing for a Marketing Authorization Application for Tanruprubart in Guillain-Barré Syndrome by January 2026, and anticipates pivotal data for Vonaprument in Geographic Atrophy later in 2026. Their financial stability allows continued advancement of multiple key programs into 2027.
Read more →ANNXAnnexon Biosciences to Participate in Upcoming September Investor Conferences
Annexon Biosciences announced its participation in several investor conferences in September, featuring CEO Douglas Love in fireside chats. The company focuses on developing therapies for neuroinflammatory diseases by targeting C1q, aiming to address significant unmet medical needs. The presentations will be accessible via live webcasts and archived for later viewing.
Read more →ANNX▼ -8.5%on this newsshared move
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipa
Annexon, Inc. has released its second quarter 2025 financial results, highlighting significant portfolio progress and upcoming regulatory milestones. The company expects to submit a Marketing Authorization Application (MAA) for tanruprubart, a treatment for Guillain-Barr syndrome, in early 2026. Additionally, they have accelerated enrollment in the Phase 3 ARCHER II trial for vonaprument, targeting dry age-related macular degeneration. With a robust financial position of $227 million, Annexon is well-prepared to advance its late-stage clinical programs into 2026.
Read more →ANNXAnnexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
Annexon has announced that the European Medicines Agency (EMA) selected its drug vonaprument to participate in the Product Development Coordinator pilot. This program aims to facilitate regulatory interactions and support evidence planning for the treatment of dry age-related macular degeneration with geographic atrophy. Vonaprument is positioned as a potential first treatment approved for this condition in Europe and the U.S., with promising results in preserving vision.
Read more →ANNXAnnexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
Annexon has completed enrollment for its pivotal Phase 3 ARCHER II trial of vonaprument for dry age-related macular degeneration with geographic atrophy. The trial has exceeded its enrollment target of 630 participants, reflecting strong demand for vision-preserving therapies. Topline data is anticipated in the second half of 2026, with the potential for vonaprument to be the first treatment approved for this condition in both Europe and the U.S.
Read more →ANNXAnnexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
Annexon has appointed Dr. Lloyd Clark as senior vice president of ophthalmology strategy, enhancing its expertise as the ANX007 program advances in treating dry age-related macular degeneration (AMD) with geographic atrophy (GA). ANX007 is the only investigational therapy shown to significantly preserve vision in this patient population. The Phase 3 ARCHER II trial is expected to complete enrollment by Q3 2025, with topline data anticipated in late 2026.
Read more →ANNX▼ -6.4%on this news
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
Annexon Biosciences will present at the Jefferies Global Healthcare Conference on June 4, 2025. Douglas Love, the CEO, will discuss the company's innovative therapies aimed at treating classical complement-mediated neuroinflammatory diseases. The event will be accessible via a live webcast, with a replay available for 30 days post-presentation.
Read more →ANNX▲ +10.6%on this news
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Q
Annexon reported its Q1 2025 financial results, highlighting key milestones in its clinical portfolio including the anticipated FDA meeting for Tanruprubart in Guillain-Barr syndrome (GBS) and positive progress in the Phase 3 ARCHER II trial for ANX007 focusing on dry age-related macular degeneration. The company's innovative therapies are targeting significant unmet needs, particularly in GBS where no FDA-approved treatments currently exist. Financially, Annexon holds substantial cash reserves to support ongoing operations and milestone achievements well into 2026.
Read more →ANNXAnnexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
Annexon, Inc. announced upcoming presentations on the neuroprotective effects of its investigational therapy, ANX007, at the 2025 ARVO Annual Meeting and the Retina World Congress. The Phase 2 ARCHER trial results support the drug's potential to prevent vision loss in patients with dry age-related macular degeneration (AMD) and geographic atrophy (GA). ANX007, which blocks the C1q protein, has received significant regulatory designations, including Fast Track and PRIME in Europe, indicating its importance in treating these conditions. The company is also moving forward with Phase 3 trials to further evaluate its efficacy.
Read more →ANNX▼ -9.5%on this news
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Tar
Annexon, Inc. reported its fourth quarter and year-end 2024 financial results, showcasing significant progress across its therapeutic portfolio. The company highlighted strong Phase 3 data for ANX005, potentially the first targeted therapy for Guillain-Barr syndrome, with a pre-BLA meeting scheduled for early 2025. Additionally, Annexon established a global registration path for ANX007 targeting dry age-related macular degeneration, with Phase 3 data expected in late 2026. The financial results reflect a solid position with over $312 million in cash, ensuring operational continuity into the latter half of 2026.
Read more →ANNXAnnexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
Annexon Biosciences has announced that its CEO, Douglas Love, will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025. The company is known for developing novel therapies aimed at treating classical complement-mediated neuroinflammatory diseases. Their approach targets C1q, a key molecule in the inflammatory pathway, to prevent tissue damage and neurodegeneration. This presentation highlights the company's commitment to advancing therapeutics that cater to significant unmet medical needs.
Read more →ANNXAnnexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
Annexon, Inc. has announced key presentations on its investigational therapy ANX007 during the Macula Society's 48th Annual Meeting. ANX007, a first-in-kind antigen-binding fragment, has demonstrated significant capacity for vision preservation in patients with geographic atrophy, as established in the Phase 2 ARCHER trial. The therapy has also received regulatory designations from both the FDA and the European Union, enhancing its development prospects. Presenters from esteemed institutions are providing insights on the implications of C1q inhibition related to neurodegeneration and visual function preservation.
Read more →ANNXAnnexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year ANX005 First Potential Targeted Therapy for Guillain-Barr Syndrome Advancing Towards 1H 2025 BLA Submission ANX007 First Potential Ne
Annexon provides an optimistic 2025 outlook, highlighting its flagship programs, including ANX005, targeted for Guillain-Barr syndrome with a BLA submission in the first half of 2025. The company aims to replicate the success of ANX007 in the Phase 3 ARCHER II trial, and anticipates clinical proof of concept for ANX1502 in early 2025. With a financial runway until mid-2026, Annexon is poised for significant advancements in its complement-mediated therapies across various neuroinflammatory diseases.
Read more →ANNXAnnexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations
Annexon, Inc. announced the appointment of William BJ Jones to its board of directors, highlighting his extensive experience in biotech commercialization. Jones has held critical roles in various leading pharmaceutical companies and is expected to bring valuable expertise as the company approaches the commercialization of its products ANX005 and ANX007. His background supports Annexon’s mission to develop novel therapies for neuroinflammatory diseases, with an emphasis on complement-targeted treatments.
Read more →ANNXAnnexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Annexon Biosciences, a biopharmaceutical company focused on therapies for neuroinflammatory diseases, announced that CEO Douglas Love will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The presentation is part of their efforts to showcase their innovative approach targeting C1q in complement-driven conditions. With a pipeline addressing autoimmune, neurodegenerative, and ophthalmic diseases, the company aims to provide transformative therapies for millions affected by these conditions. A live webcast of the event will be available publicly.
Read more →ANNX▲ +14%on this news
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-
Annexon has announced positive topline results from a real-world evidence study demonstrating the efficacy of their drug ANX005 for treating Guillain-Barr Syndrome (GBS). The study compared ANX005 treatment to Intravenous Immunoglobulin (IVIg) and Plasma Exchange (PE) and found significant benefits in muscle strength and functional outcomes. Patients treated with ANX005 experienced faster recovery and required less mechanical ventilation. These encouraging results contribute to the body of evidence supporting ANX005 as a potential treatment for GBS, which currently has no FDA-approved therapies.
Read more →ANNXAnnexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
Annexon, Inc. recently announced it will present data on ANX007 from its completed Phase 2 ARCHER trial for geographic atrophy at the Floretina-ICOOR 2024 meeting. The data highlights ANX007's significant protection against vision loss and preservation of photoreceptors, showing promise for patients with dry age-related macular degeneration. The company is also actively enrolling patients for the pivotal Phase 3 ARCHER II trial, with topline data expected in the second half of 2026.
Read more →ANNXAnnexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barr Syndrome (GBS) Expected by
Annexon reported its third quarter 2024 results, highlighting significant advances in its portfolio, including the promising ANX005 for Guillain-Barr syndrome with a key BLA submission targeted for 2025. The company is also enrolling patients for its Phase 3 ARCHER II trial for ANX007 in Geographic Atrophy, with topline data expected in late 2026. Despite a robust cash position of $340 million, the company reported a net loss, although leadership changes aim to facilitate upcoming commercialization efforts for ANX005. The company remains focused on delivering results from its clinical programs and achieving its mission of addressing neuroinflammatory diseases.
Read more →ANNXAnnexon Biosciences to Present at the Jefferies London Healthcare Conference
Annexon, Inc. announced that its CEO, Douglas Love, will present at the Jefferies London Healthcare Conference on November 20, 2024. The company is focused on developing therapies for neuroinflammatory diseases, using a novel approach that targets the C1q molecule. This presentation aims to showcase their advancements in this area, which could benefit millions affected by such conditions. A live webcast will be available for those interested in the event.
Read more →ANNXAnnexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting Enhanced protection of vision with ANX007 treatment in healthi
Annexon presented new Phase 2 data for ANX007 at the AAAO 2024, demonstrating enhanced vision protection and photoreceptor preservation in patients with less advanced geographic atrophy due to dry AMD. The data suggests ANX007 may offer significant benefits compared to existing treatments and indicates its potential for widespread use in affected populations. Additionally, Phase 3 results are anticipated in the latter half of 2026, highlighting the ongoing development of this innovative therapy.
Read more →ANNXAnnexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Annexon, Inc. announced that it will present new Phase 2 ARCHER trial data for ANX007, a treatment for geographic atrophy, at the AAO 2024 annual meeting. The results indicate that ANX007 effectively protects vision in patients under both standard and low light conditions. The therapy also preserves critical photoreceptor structures and has been positively received by regulatory authorities like the FDA and the EU. The significant findings suggest a potential for long-term therapeutic benefits in treating dry age-related macular degeneration.
Read more →ANNX▲ +8.2%on this news
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
Annexon, Inc. announced the presentation of Phase 2 ARCHER trial data for its drug ANX007 at upcoming retina conferences in Portugal and Spain. The findings demonstrate significant vision protection and preservation of photoreceptors in patients with geographic atrophy (GA). Following positive results, a Phase 3 ARCHER II trial has been initiated, with data anticipated in the second half of 2026. ANX007 is positioned as a first-in-kind treatment designed to inhibit C1q, crucial for addressing neurodegeneration associated with GA.
Read more →ANNX▼ -5.1%on this news
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
Annexon, Inc. has announced the expansion of its senior leadership team by hiring three experienced executives in commercial, medical affairs, and health economics. The appointments are aimed at advancing the company's late-stage neuroinflammatory-targeted portfolio, particularly programs in Guillain-Barré Syndrome and geographic atrophy. The new leaders bring extensive experience from prior roles at prominent biopharmaceutical companies, positioning Annexon for potential growth in a competitive market. This strategic move reflects the company's commitment to addressing the needs of patients with neuroinflammatory diseases.
Read more →ANNXAnnexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones Single, Well-Tolerated Infusion of ANX005 Significantly Accelerated Recovery of GBS Patients vs. Placebo in Pivotal Phas
Annexon reported its second quarter 2024 financial results, highlighting significant progress in its clinical pipeline. The pivotal trial for ANX005 demonstrated a notable acceleration in recovery for Guillain-Barr syndrome patients versus placebo. The company also initiated dosing in the ARCHER II trial for ANX007, which focuses on geographic atrophy, and successfully completed a bridging study for the oral inhibitor ANX1502. Annexon boasts a strong cash position expected to support its operations into late 2026 and anticipates key data milestones in the coming months.
Read more →ANNX▼ -9.4%on this news
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Additional D
Annexon has initiated patient dosing in its global Phase 3 ARCHER II trial for the C1q inhibitor ANX007, aimed at treating geographic atrophy (GA). Recent data from the Phase 2 ARCHER trial indicated ANX007's effectiveness in protecting both vision and critical retinal structures, suggesting its potential as a first-in-class therapy. The study is set to compare ANX007 against sham controls with topline data forecasted for the second half of 2026. This marks a significant step forward in addressing a currently unmet need for vision protection in GA treatment.
Read more →ANNX▲ +8.5%on this news· ran to +23% by day 3shared move
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Annexon, Inc. announced it will present additional Phase 2 data on ANX007, a novel therapy for Geographic Atrophy, at the upcoming ASRS Annual Scientific Meeting. The data will highlight ANX007's protective effects on visual acuity and relevant anatomical measures in the central macula. Notably, recent trial results indicated a statistically significant reduction in vision loss among treated patients. The drug has received both Fast Track and PRIME designations, indicating its potential for significant impact in treating vision loss associated with Geographic Atrophy.
Read more →ANNXAnnexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting ANX005-Treated Patients Demonstrated Faster and More Complete Recovery
Annexon, Inc. presented positive Phase 3 results for ANX005, a C1q-targeted immunotherapy for Guillain-Barr Syndrome (GBS), at the 2024 PNS Annual Meeting. The trial showed that patients treated with ANX005 experienced faster and more complete recovery than those on placebo, with particular benefits noted in patients with North American and European characteristics. ANX005's safety profile was similar to that of placebo, reinforcing its potential as a first-in-class targeted treatment for GBS. The results highlighted the urgent need for effective therapies in the GBS treatment landscape.
Read more →ANNX▲ +13.4%on this news
Annexon Announces Pricing of $125 Million Underwritten Public Offering
Annexon, Inc. has announced the pricing of a public offering aimed at raising $125 million through the sale of 13,001,120 shares at $6.25 each. The offering also includes pre-funded warrants for certain investors. The proceeds will support Annexon's clinical development of therapies for complement-mediated neuroinflammatory diseases. The offering is set to close on June 7, 2024, pending customary conditions. Leading banks are managing the offering, which is registered under an SEC filing.
Read more →ANNX▲ +30.8%on this news· ran to +48% by day 1shared move
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barr Syndrome Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly
Annexon announced positive topline results from its pivotal Phase 3 trial for ANX005, a C1q blocking antibody aimed at treating Guillain-Barr syndrome (GBS). The trial demonstrated a 2.4-fold improvement in the GBS-disability scale at week 8, with significant gains in muscle strength and reduced time on ventilation. ANX005 was well-tolerated with no major safety concerns, supporting its potential as the first targeted treatment for GBS. The company anticipates further data and regulatory submissions in the coming years.
Read more →ANNX▲ +30.8%on this news· ran to +48% by day 1shared move
Annexon Announces Proposed Public Offering of Common Stock
Annexon, Inc. has announced a proposed underwritten public offering of $125 million worth of its common stock, with an option for underwriters to purchase an additional $18.75 million. The offering is intended to support their late-stage clinical platform for therapies targeting neuroinflammatory diseases. The final terms of the offering will be disclosed in a subsequent prospectus, but its completion is uncertain due to market conditions. The company seeks to utilize the funds to further advance its clinical trials for novel therapies.
Read more →ANNX▼ -5.2%on this news· ran to +24% by day 1shared move
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
Annexon, Inc. will host a conference call and webcast on June 4, 2024, to discuss the results from their Phase 3 trials focusing on Guillain-Barré syndrome (GBS). The company is developing a new class of complement-based medicines to treat neuroinflammatory conditions, and it is advancing its clinical trials to provide new treatments for patients. The webcast will be accessible through their website, with dial-in options for participants.
Read more →ANNXAnnexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barr Syndrome
Annexon has reported its first quarter 2024 financial results, showcasing multiple anticipated milestones for its clinical programs. Pivotal Phase 3 data for ANX005 in Guillain-Barr Syndrome is expected in the second quarter of 2024, while promising Phase 2 data for ANX007 in Geographic Atrophy was presented at ARVO 2024. The company maintains a robust financial position with approximately $264.9 million in cash, providing a significant runway for future operations and trials. The upcoming year is highlighted as transformative with multiple value-creating catalysts grounded in comprehensive research.
Read more →ANNXAnnexon Biosciences to Present at the Bank of America Health Care Conference
Annexon Biosciences, a biopharmaceutical company focused on therapies for neuroinflammatory diseases, announced that CEO Douglas Love will present at the Bank of America Health Care Conference on May 14, 2024. The company's innovative therapies target inflammatory processes to benefit patients with various autoimmune and neurodegenerative conditions. Annexon has shared promising proof-of-concept data for its treatments in conditions like Guillain-Barré syndrome and Huntington's disease. A live webcast of the event will be available, with replays accessible for 30 days thereafter.
Read more →ANNXAnnexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting ANX007 demonstrated significant, broad-based protection from vis
At the ARVO 2024 Annual Meeting, Annexon presented promising new data regarding ANX007, demonstrating its ability to protect vision in patients with geographic atrophy. The results showed significant preservation of retinal structures and visual function, supported by preclinical evidence of its neuroprotective actions. With the initiation of pivotal Phase 3 trials expected in mid to late 2024, the findings underscore the potential of ANX007 in the competitive treatment landscape for vision loss. This treatment is notable for receiving Priority Medicine designation from the European Medicines Agency.
Read more →ANNXAnnexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
Annexon, Inc. is set to present new data at the ARVO 2024 Annual Meeting, showcasing the neuroprotective effects of ANX007 and C1q inhibition in geographic atrophy (GA). The presentations will include additional results from the Phase 2 ARCHER trial, demonstrating ANX007's ability to protect visual acuity and preserve photoreceptor function. New preclinical findings will also highlight the role of C1q in photoreceptor synapse elimination. The presentations are scheduled for May 7, 2024, in Seattle, Washington.
Read more →ANNXAnnexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Annexon Biosciences has announced that its CEO, Douglas Love, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024. The company focuses on late-stage clinical therapies for neuroinflammatory diseases, including Guillain-Barré syndrome and Huntington's disease. Annexon aims to provide meaningful benefits through its novel approach targeting the classical complement inflammatory cascade. A live webcast of the event will be available on their website, along with a replay for 30 days after the presentation.
Read more →ANNXAnnexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones Pivotal Phase 3 Data for ANX005 in Guillain-Barr Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phas
Annexon, Inc. recently reported its fourth quarter and year-end 2023 financial results, highlighting key milestones for its clinical pipeline. The company anticipates pivotal Phase 3 data for its lead candidate ANX005 in Guillain-Barr Syndrome (GBS) in the second quarter of 2024. Following a successful $125 million financing, Annexon is well-positioned with a robust cash balance expected to support operations into mid-2026. Additionally, the company plans to initiate pivotal trials for ANX007 in Geographic Atrophy later in 2024, underscoring its commitment to advancing innovative therapies.
Read more →ANNX▲ +7.2%on this news
Virtual R&D Day |
Annexon Biosciences held a virtual R&D day focusing on its commitment to developing treatments for Guillain-Barr Syndrome (GBS). The company's lead candidate, ANX005, aims to be the first FDA-approved therapy for GBS, with pivotal data expected in Q2 2024. The session featured insights from company leadership and external experts, highlighting the significant unmet medical needs in GBS and the potential market for their innovative therapies. Additionally, the presentation underscored the importance of patient experiences and ongoing clinical trials as part of Annexon’s dedication to GBS treatments.
Read more →ANNXAnnexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
Annexon Biosciences, a clinical-stage biopharmaceutical company, announced that CEO Douglas Love will participate in a corporate panel discussion at the TD Cowen 44th Annual Health Care Conference. The event is set to occur on March 5, 2024, in Boston, MA. Annexon focuses on developing complement-based therapies aimed at treating severe inflammatory diseases, with ongoing clinical trials showing promising proof-of-concept results in conditions like Guillain-Barré syndrome and geographic atrophy.
Read more →ANNXAnnexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases ANX005 Phase 3 Pivotal Data in Guillain-Barr Syndrome (G
Annexon, Inc. has outlined its strategic priorities for 2024, focusing on significant clinical milestones for its complement-based therapies. The company expects to release pivotal Phase 3 trial data for ANX005 targeting Guillain-Barr syndrome in the first half of 2024, potentially making it the first approved treatment for this condition in the U.S. Additionally, the global pivotal program for ANX007 in geographic atrophy will be initiated mid-2024, while proof-of-concept trials for ANX1502, an oral small molecule inhibitor, are also set to begin. Recent financing has strengthened the company's resources to advance its promising portfolio of therapies.
Read more →ANNXAnnexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Annexon Biosciences, a clinical-stage biopharmaceutical company, has announced that its CEO, Douglas Love, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024. The presentation will provide insights into their pipeline of complement-based medicines aimed at addressing inflammatory-related diseases. The company emphasizes its exclusive focus on targeting C1q to mitigate the inflammatory response. They are advancing mid-to-late-stage clinical trials, with positive data in Guillain-Barré syndrome and geographic atrophy.
Read more →ANNXAnnexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
Annexon, Inc. has announced the pricing of a $125 million underwritten public offering, set to close on December 26, 2023. The offering includes approximately 25 million shares of common stock priced at $2.880 per share and pre-funded warrants. This fundraising aims to bolster the company's pipeline of complement medicines targeting autoimmune, neurodegenerative, and ophthalmic disorders. Despite its progress, the company acknowledges potential risks related to market conditions and offerings in its forward-looking statements.
Read more →ANNXAnnexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint Alignment with FDA on Best Corrected Visual Acuity 15-Letter Loss as Primary O
Annexon has announced its global registrational program for ANX007, a complement inhibitor aimed at treating geographic atrophy (GA), with alignment from the FDA on critical outcome measures. This program includes the Phase 3 ARCHER II trial, which will start enrollment in mid-2024, and a head-to-head trial against SYFOVRE called ARROW, anticipated to begin in late 2024. The focus on vision preservation and the potential efficacy demonstrated in previous trials positions ANX007 as a promising candidate for patients suffering from GA.
Read more →ANNXAnnexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
Annexon, Inc. has reported successful Phase 1 results for its oral small molecule inhibitor, ANX1502, showing target drug levels in healthy volunteers. The drug was well tolerated across various dose cohorts without any serious adverse events, leading to plans for a proof-of-concept study in patients with cold agglutinin disease in 2024. This development marks a significant step in clinical research aimed at addressing autoimmune conditions through innovative complement-based therapies.
Read more →ANNXAnnexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Annexon Biosciences, a clinical-stage biopharmaceutical company, will have its CEO Douglas Love participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023. The conference aims to highlight advancements in health and pharmaceuticals. Annexon is known for its novel approach to develop therapies targeting the classical complement pathway, with ongoing trials for conditions like Guillain-Barré syndrome and geographic atrophy. This event presents a platform for the company to share insights into its research and development efforts.
Read more →ANNX▲ +6.4%on this news· ran to +20% by day 3
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barr Syndrome (GBS), ANX007 for
Annexon, Inc. announced significant progress in its clinical programs during Q3 2023, particularly with ANX005 for Guillain-Barr Syndrome and ANX007 for Geographic Atrophy, the latter receiving EMA's PRIME designation. The company reported robust enrollment in its pivotal trial for GBS, with results anticipated in the first half of 2024, while maintaining a healthy financial position. Annexon aims to accelerate the development of its priority treatments and has planned significant upcoming milestones.
Read more →ANNXAnnexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference
Annexon Biosciences announced its participation in the 2023 Jefferies London Healthcare Conference, where CEO Douglas Love will engage in a fireside chat. The conference is scheduled for November 15, 2023. Annexon is distinguished in developing therapies that target the classical complement pathway, particularly C1q, aiming to address various inflammatory-related diseases. The company has demonstrated proof-of-concept in significant conditions, including Guillain-Barré syndrome and geographic atrophy, as it advances its clinical pipeline.
Read more →ANNX▲ +8.3%on this news· ran to +24% by day 3
ANNEXON RECEIVES PRIME DESIGNATION FROM THE EMA FOR ANX007 FOR THE TREATMENT OF GEOGRAPHIC ATROPHY PRIME Designation Granted Based on Phase 2 ARCHER Trial Results, which Showed Meaningful Preservation of Visual Function
Annexon, Inc. announced that the European Medicines Agency has granted PRIME designation to ANX007 for treating geographic atrophy associated with age-related macular degeneration. This designation follows promising results from the Phase 2 ARCHER trial, which indicated a significant preservation of visual function in patients receiving ANX007. The company intends to collaborate with regulatory authorities in the U.S. and EU to expedite the development process for a pivotal Phase 3 trial.
Read more →ANNXANNEXON ANNOUNCES CLINICAL AND REGULATORY PROGRESS FOR ANX005 PIVOTAL PROGRAM IN GUILLAIN-BARRÉ SYNDROME (GBS)
Annexon, Inc. has announced significant progress for its investigational therapy ANX005 for Guillain-Barré Syndrome (GBS), including receiving orphan drug designation from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The recent designation stems from promising clinical data indicating ANX005 may offer advantages over existing treatments. The company has also successfully enrolled 225 patients in its Phase 3 clinical trial and anticipates releasing results in the first half of 2024. GBS is a serious condition affecting approximately 12,000 people annually in the U.S. and Europe, currently lacking approved therapies.
Read more →ANNXAnnexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
Annexon Biosciences is set to participate in the upcoming 2023 Cantor Global Healthcare Conference, with CEO Douglas Love scheduled for a fireside chat. The conference will take place on September 26, 2023, in New York City. Annexon is focused on developing complement-based medicines for various autoimmune, neurodegenerative, and ophthalmic disorders. The company aims to preserve beneficial immune functions while addressing inflammation caused by an overactivated immune response.
Read more →ANNXAnnexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geogr
Annexon, Inc. has reported a successful second quarter of 2023, highlighting advancements in its clinical portfolio, particularly in complement therapies aimed at autoimmune and neurodegenerative diseases. The company announced positive results from its ARCHER trial, further supporting the efficacy of its lead compound ANX007 in preserving visual function in geographic atrophy patients. Looking forward, Annexon plans to complete pivotal trial enrollment for ANX005 in Guillain-Barr Syndrome while navigating regulatory engagements for ANX007. With a strong financial position, the company's operating runway extends through 2025, enabling continued progression of its research and development efforts.
Read more →ANNX▲ +7.5%on this newsshared move
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
Annexon presented encouraging results from the ARCHER trial at ASRS 2023, highlighting the potential of ANX007 as an effective treatment for geographic atrophy (GA). The trial demonstrated significant, dose-dependent protection against vision loss, backed by consistent data across various assessments. While not all primary endpoints achieved statistical significance, further analyses indicated a potential increasing effect over time. Annexon plans regulatory discussions and an investor call following these promising findings.
Read more →ANNX▼ -6.8%on this newsshared move
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
Annexon Biosciences has appointed Jamie Dananberg, M.D., as the new Chief Medical Officer. This move is seen as a strategic enhancement to Annexon's leadership, particularly given Dr. Dananberg's extensive experience in drug development across various therapeutic areas. The company specializes in developing complement-based treatments for autoimmune and neurodegenerative disorders. The announcement emphasizes a positive outlook for the company, as it prepares for crucial clinical data readouts in the coming months.
Read more →ANNXAnnexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
Annexon, Inc. announced that it will present results from its ARCHER Phase 2 trial, which investigates the treatment of geographic atrophy due to age-related macular degeneration, at the upcoming ASRS 2023 Annual Meeting. The presentation is scheduled for July 30, 2023, with Dr. Jeffrey S. Heier leading the discussion. This trial is part of Annexon's efforts to develop a new class of complement-based medicines aimed at treating various autoimmune and neurodegenerative disorders. The results could have significant implications for patients suffering from this condition.
Read more →ANNX▼ -7.8%on this news· ran to -63% by day 1
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function ARCHER data support ANX007 as the first complement the
Annexon, Inc. announced positive topline data from its ARCHER Phase 2 trial of ANX007, showcasing a statistically significant, dose-dependent preservation of visual function in geographic atrophy patients. The treatment demonstrated a 72% reduction in the risk of significant vision loss among monthly treated patients, marking a notable advancement in complement-based therapies. Although the primary endpoint regarding lesion growth was not statistically significant, the results indicate potential for ANX007 in improving the quality of life for patients suffering from this condition. The company plans to engage with regulatory agencies to explore the path forward for ANX007.
Read more →ANNXAnnexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress Initial Clinical Data Expected from the Phase 2 ARCHER Trial of ANX007 in Geographic Atrophy in Mid-2023 Initial Clinical Data
Annexon, Inc. reported its first-quarter financial results, highlighting significant advancements in its clinical pipeline, specifically for ANX007 and ANX009. The company expects initial clinical data from the Phase 2 ARCHER trial of ANX007 in geographic atrophy and from the Phase 1b trial of ANX009 in lupus nephritis to be available in 2023. Additionally, they are progressing well in their pivotal trial for Guillain-Barr syndrome with results expected by early 2024. Despite a net loss reported for the quarter, Annexon maintains a strong financial position to support its ongoing and future clinical trials.
Read more →ANNX▲ +5.9%on this news
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
Annexon Biosciences is set to participate in the 22nd Annual Needham Virtual Healthcare Conference, with CEO Douglas Love featured in a fireside chat on April 18, 2023. The company focuses on developing a new class of complement medicines aimed at treating autoimmune, neurodegenerative, and ophthalmic disorders. This engagement at the conference is expected to enhance visibility for their innovative therapies currently in development.
Read more →ANNX▼ -6.8%on this news
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones Initial Clinical Data from Phase 2 Trial of ANX007 in Patients with Geographic Atrophy On-track for Mid-2023 Oral S
Annexon, Inc. reported its fourth quarter and year-end 2022 financial results, highlighting a robust cash position of $242.7 million that extends its operational runway into 2025. The company remains focused on advancing its clinical pipeline, including anticipated data from the Phase 2 trial of ANX007 for geographic atrophy in mid-2023, while also progressing its oral candidate ANX1502 through a multi-ascending dose trial. Despite a reported net loss, Annexon emphasized its solid foundation and milestones for the coming years focused on autoimmune and neurodegenerative disorders.
Read more →ANNXAnnexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
Annexon Biosciences, a clinical-stage biopharmaceutical company, announced that its CEO, Douglas Love, will participate in the 43rd Annual Cowen Healthcare Conference on March 6, 2023. The event provides an opportunity for the company to discuss its innovative complement medicines targeting autoimmune, neurodegenerative, and ophthalmic disorders. Annexon is focused on developing therapies that preserve beneficial immune functions while addressing these complex diseases. The conference is expected to enhance the company's visibility among investors and stakeholders in the healthcare sector.
Read more →ANNXGAME-CHANGING MEDICINES FOR COMPLEMENT- MEDIATED DISEASES JANUARY 2023 Nasdaq: ANNX 1 Forward-Looking Statements This presentation contains "forward looking" statements about Annexon, Inc. the outcomes of any future coll
Annexon, Inc. has presented a detailed update on its clinical programs focused on complement-mediated diseases, highlighting promising clinical outcomes related to its lead candidate ANX005. The company aims to address autoimmune and neurodegenerative conditions through innovative therapies with broad market potential, estimated at $10B. In particular, ANX005 has shown positive results in patients with Guillain-Barr Syndrome and Huntington's Disease, with favorable safety profiles established. Annexon is well-capitalized, providing it with a timeline to advance its clinical programs through 2025.
Read more →ANNXAnnexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
Annexon, Inc. has highlighted its strategic focus on advancing four flagship complement programs through late-stage development, targeting Guillain-Barré syndrome, Huntington’s disease, and geographic atrophy among others. The company has made significant progress with key clinical trials set to achieve multiple catalysts by the end of 2023, including pivotal trials for their therapies ANX005 and ANX1502. Additionally, Annexon aims to enhance patient outcomes through a broad portfolio of therapies designed to target classical complement-mediated diseases. The company plans to present updates on their pipeline at the 41st Annual J.P. Morgan Healthcare Conference in January 2023.
Read more →ANNX▲ +5.3%on this news· ran to +17% by day 3shared move
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio
Annexon, Inc. has appointed Dr. Rick Artis as the new Chief Scientific Officer, succeeding Larry C. Mattheakis. Dr. Artis, an industry veteran with extensive experience in complement biology and drug development, will lead research efforts to enhance and expand the company's complement-focused portfolio. The company is optimistic about its pipeline and anticipates significant clinical data readouts throughout 2023 and beyond. This strategic appointment aims to propel the company towards its mission of developing innovative therapies for complement-mediated diseases.
Read more →ANNXAnnexon to Present at 41st Annual J.P. Morgan Healthcare Conference
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The CEO, Douglas Love, will discuss the company's advancements in a novel class of complement medicines aimed at treating autoimmune, neurodegenerative, and ophthalmic disorders. Annexon is actively developing a robust pipeline and plans to present several clinical readouts in 2023. The event can be accessed via a live webcast on their website, which will be available for 30 days post-presentation.
Read more →ANNXAnnexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023 Company to provide portfolio updates across autoimmune, neurodegeneration and ophthalm
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023 Company to provide portfolio updates across autoimmune, neurodegeneration and ophthalmology therapeutic franchises in early January Presentation
Read more →ANNXAnnexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Followin
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations Multiple Cl
Read more →ANNX▼ -13.9%on this news
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025
BRISBANE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, toda
Read more →ANNX▲ +14.4%on this newsshared move
Annexon Announces $130 Million Private Placement Financing
Annexon Announces $130 Million Private Placement Financing BRISBANE, Calif., July 8, 2022 Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodeg
Read more →ANNX▲ +24.9%on this news
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington s Disease ANX005 Demonstrated Full C1q Target Inhibition an
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington s Disease ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabi
Read more →ANNXAnnexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, toda
Read more →ANNX▼ -5.1%on this newsshared move
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, toda
Read more →ANNXAnnexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentia
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalys
Read more →ANNXAnnexon Biosciences to Participate in Upcoming May Investor Conferences
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today
Read more →ANNX▼ -5.3%on this news
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy Topline efficacy and safety data expected in first half of 2023
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy Topline efficacy and safety data expected in first half of 2023 BRISBANE, Calif., Apr. 7, 2022 - Annexon, Inc. (Nasdaq: ANNX), a clinical-stage
Read more →ANNX▲ +15.4%on this newsshared move
Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, tod
Read more →ANNXAnnexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023 Encouraging
Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023 Encouraging Interim Data Reported from Phase 2 Study of ANX005 for Hu
Read more →ANNX▼ -5.5%on this newsshared move
Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference
BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, tod
Read more →ANNXAnnexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors
Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors BRISBANE, Calif., January 20, 2022 - Annexon, Inc. ( Annexon ) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical
Read more →ANNX▲ +5.4%on this news
th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY 11, 2022 Forward-looking Statements This presentation and accompanying oral presentation contain "forward looking" statements about Annexon, Inc. and our industr y that
Forward-looking Statements This presentation and accompanying oral presentation contain "forward looking" statements about Annexon, Inc. and our industr y that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statem
Read more →ANNX▼ -7.8%on this news· ran to -39% by day 1
Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington s Disease Following Six-Month Treatment ANX005 Has Been Generally Well-Tolerated and Has Shown
Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington s Disease Following Six-Month Treatment ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF Improvements i
Read more →ANNX▼ -7.8%on this news· ran to -39% by day 1
Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, toda
Read more →ANNX▼ -6.2%on this news· ran to -19% by day 3
Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition
BRISBANE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, anno
Read more →ANNXAnnexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results $271 Million Cash and Investments at End of Third Quarter 2021 Supports Operating Runway into 2024, Including
Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results $271 Million Cash and Investments at End of Third Quarter 2021 Supports Operating Runway into 2024, Including Several Key Clinical Milestones across the Portfolio SOUT
Read more →ANNXANNEXON BIOSCIENCES FURTHER STRENGTHENS ITS EXECUTIVE LEADERSHIP TEAM WITH APPOINTMENT OF TED YEDNOCK, PH.D., TO CHIEF INNOVATION OFFICER AND APPOINTMENT OF LARRY MATTHEAKIS, PH.D., AS CHIEF SCIENTIFIC OFFICER Dr. Ted Ye
ANNEXON BIOSCIENCES FURTHER STRENGTHENS ITS EXECUTIVE LEADERSHIP TEAM WITH APPOINTMENT OF TED YEDNOCK, PH.D., TO CHIEF INNOVATION OFFICER AND APPOINTMENT OF LARRY MATTHEAKIS, PH.D., AS CHIEF SCIENTIFIC OFFICER Dr. Ted Yednock s appointment enhances Annexon s commitment to scie
Read more →ANNXAnnexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic d
Read more →ANNXAnnexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic d
Read more →ANNXAnnexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update - Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically exp
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update - Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases - - Con
Read more →ANNXAnnexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases Adva ncing subcutaneous ANX009 candidate into Phase 1b program in L
Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases Advancing subcutaneous ANX009 candidate into Phase 1b program in Lupus Nephritis Deepening ANX005 neuromuscular autoimmune p
Read more →ANNXAnnexon to Present at the Raymond James Human Health Innovation Conference
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative dis
Read more →ANNXAnnexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results - ANX005 Huntington's Disease Phase 2 trial fully enrolled with data anticipated 2H 2021 - - ANX009 First-in-Human dose-rangin
Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results - ANX005 Huntington's Disease Phase 2 trial fully enrolled with data anticipated 2H 2021 - - ANX009 First-in-Human dose-ranging trial completed with data expected summer 2021 - - Next
Read more →ANNXAnnexon to Present at the BofA Securities 2021 Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disor
Read more →ANNXAnnexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights
Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights SOUTH SAN FRANCISCO, Calif., March 25, 2021 - Today Annexon, Inc. ("Annexon") (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of nove
Read more →ANNXAnnexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy
SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced t
Read more →ANNXAnnexon Welcomes William H. Carson, M.D. to the Board of Directors Thomas G. Wiggans appointed Chairman
Annexon Welcomes William H. Carson, M.D. to the Board of Directors Thomas G. Wiggans appointed Chairman SOUTH SAN FRANCISCO, Calif., February 8, 2021 (GLOBE NEWSWIRE) Annexon, Inc. ( Annexon ) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of
Read more →ANNXAnnexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Complement Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders
Read more →ANNXSTOPPING CLASSICAL COMPLEMENT AT THE START TREATING DISEASES OF THE BODY, BRAIN AND EYE COMPANY PRESENTATION JANUARY 11, 2021 Disclaimer This presentation contains "forward looking" statements about Annexon, Inc. and our
DISEASES OF THE BODY, BRAIN AND EYE COMPANY PRESENTATION JANUARY 11, 2021Exhibit 99.1 STOPPING CLASSICAL COMPLEMENT AT THE START TREATING DISEASES OF THE BODY, BRAIN AND EYE COMPANY PRESENTATION JANUARY 11, 2021 Disclaimer This presentation contains "forward looking" statements
Read more →ANNXAnnexon to Present at the J.P. Morgan 39th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders
Read more →ANNXAnnexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights - Cash balance of $370.7 million as of
Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights - Cash balance of $370.7 million as of September 30, 2020 bolstered by July IPO - - Recently expanded ANX005 clinical program into neurodegeneration, with initiation of Phase 2 in Hu
Read more →ANNXAnnexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program
– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with clas
Read more →ANNXAnnexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights Completed $263M IPO in July, and private financing in late June Company plans to initiate four new clinical trials by year-end, incl
Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights Completed $263M IPO in July, and private financing in late June Company plans to initiate four new clinical trials by year-end, including in three expanded indications for ANX005 and first-
Read more →ANNXAnnexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer
SOUTH SAN FRANCISCO, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced t
Read more →ANNXAnnexon Announces Closing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced t
Read more →ANNXAnnexon Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the pricing of i
Read more →ANNXAnnexon Closes $100 Million Financing to Advance Broad Pipeline of Classical Complement Therapeutics
SOUTH SAN FRANCISCO, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the closing of a
Read more →Competitive Position
How ANNX ranks across every disease it competes inCompetitive Position is a premium feature
See how ANNX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial